



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BLAIS et al. Examiner: [REDACTED] own  
Serial No.: 10/030,929 Group Art Unit: unknown  
Filed: 11 January 2002 Docket: 9555.126USWO

Title: METHODS FOR SELECTING AND PRODUCING SELECTIVE PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS USING AN ESTABLISHED GENETICALLY ALTERED CELL-BASED LIBRARY RESPONSIVE TO TRANSCRIPTION FACTORS: GENETIC CONSTRUCTS AND LIBRARY THEREFOR

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Office of Initial Patent Examination, Commissioner for Patents, Washington, D.C. 20231 on June 5, 2002.

  
Name: Heidi Hanson

Commissioner for Patents  
Washington, D.C. 20231


Sir:

We are transmitting herewith the attached:

- Transmittal Sheet in duplicate containing Certificate of Mailing
- Information Disclosure Statement, Form 1449, 43 References
- Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.  
P.O. Box 2903, Minneapolis, MN 55402-0903  
612.332.5300

By:   
Name: Gregory A. Sebald  
Reg. No.: 33,280  
GAS:jjh



S/N 10/030,929



PATENT

HB

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BLAIS et al. Examiner: unknown

Serial No.: 10/030,929 Group Art Unit: unknown

Filed: 11 January 2001 Docket No.: 9555.126USWO

Title: METHODS FOR SELECTING AND PRODUCING SELECTIVE PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS USING AN ESTABLISHED GENETICALLY ALTERED CELL-BASED LIBRARY RESPONSIVE TO TRANSCRIPTION FACTORS: GENETIC CONSTRUCTS AND LIBRARY THEREFOR

## CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Office of Initial Patent Examination, Commissioner for Patents, Washington, D.C. 20231 on June 5, 2002.

By:   
Name: Heidi Hanson

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: 5 June 2002

By

  
Gregory A. Sebald  
Reg. No. 33,280

GAS:hjh

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> <small>(Use several sheets if necessary)</small>			
		Docket Number: 9555.126USWO	Application Number: 10/030,929
		Applicant: BLAIS et al.	
		Filing Date: 11 January 2002	Group Art Unit: unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 766 945	16 June 1998	MILLER			
	5 863 733	26 Jan. 1999	FOULKES et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
						NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	BAULCOMBE et al. "Jellyfish green fluorescent protein as a reporter for virus infections". <i>The Plant Journal</i> , Vol. 7, No. 6, pp. 1045-1053, 1995.					
	BARTHMAIER et al. "Monitoring development and pathology of Drosophila indirect flight muscles using green fluorescent protein". <i>Developmental Biology</i> , Vol. 169, pp. 770-774, 1995.					
	BROWN et al. "An ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR $\alpha$ agonist with potent lipid-lowering activity". <i>Journal of Medical Chemistry</i> , Vol. 42, pp. 3785-3788, 1999.					
	BURNS et al. "Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells". <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 8033-8037, September 1993.					
	CHEN et al. "Prostaglandin E <sub>2</sub> and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells". <i>British Journal of Cancer</i> , Vol. 82, No. 12, pp. 2000-2006, 2000.					
	CHOW et al. "Requirement for transcription factor NFAT in interleukin-2 expression". <i>Molecular and Cellular Biology</i> , Vol. 19, pp. 2300-2307, March 1999.					
	CLIPSTONE et al. "Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation". <i>Nature</i> , Vol. 357, pp. 695-697, June 25, 1992.					
	CROSTON et al. "NF-kappa B activation by interleukin (IL-1) requires an IL-1 receptor associated protein kinase activity". <i>The Journal of Biological Chemistry</i> , Vol. 270, No. 28, pp. 16514-16517, July 14, 1995.					
	DANFORTH et al. "Interleukin 1-alpha blocks estradiol stimulated growth and down-regulates the estrogen receptor in MCF-7 breast cancer cells in vitro". <i>Cancer Research</i> , Vol. 51, pp. 1488-1493, March 1, 1991.					
	DILELLA et al. "Utility of firefly luciferase as a reported gene for promoter activity in transgenic mice". <i>Nucleic Acids Research</i> , Vol. 16, No. 9, pp. 4159, 1988.					
	DONG et al. "Inhibition of activator protein 1 activity and neoplastic transformation by aspirin". <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 15, pp. 9962-9970, 1997.					
	FITZGERALD et al. "Prostaglandine E <sub>2</sub> -induced up-regulation of c-fos messenger ribonucleic acid is primarily mediated by 3',5'-cyclic adenosine monophosphate in MC3T3-E <sub>1</sub> osteoblasts". <i>Endocrinology</i> , Vol. 141, pp. 291-298, 2000.					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation and not considered. Include copy of this form for next communication to the Applicant.	



FORM 1449* INFORMATION DISCLOSURE STATEMENT  IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 9555.126USWO	Application Number: 10/030,929
		Applicant: BLAIS et al.	
		Filing Date: 11 January 2002	Group Art Unit: unknown

*O I P E*  
JUN 13 2002  
PARENTAL TRADEMARKS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Geneka Biotechnology Inc. Catalog. <i>Immunology and Molecular Biology Products for Transcription Factors and Functional Genomics</i> , 2000.		
	HENKE et al. N-(2-benzophenyl)-L-tyrosine PPARY agonists. 1. discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. <i>Journal of Medical Chemistry</i> , Vol. 41, pp. 5020-5036, 1998.		
	HOOUJBERG et al. NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells". <i>Blood</i> , Vol. 96, No. 2, pp. 459-466, July 2000.		
	International Human Genome Sequencing Consortium. "Initial sequencing and analysis of the human genome" <i>Nature</i> , Vol. 409, pp. 860-921, February 15, 2001.		
	JAIN et al. "The T-cell transcription factor NFAT, is a substrate for calcineurin and interacts with Fos and Jun". <i>Letters to Nature</i> , Vol. 365 pp. 352-355, September 23, 1993.		
	KLIEWER et al. "Peroxisome proliferator-activated receptors: From genes to physiology". <i>Recent Prog. Horm. Res.</i> , Vol. 56, pp. 239-263, 2001.		
	KUBO et al. "Activation of the interleukin-4 gene is controlled by the unique calcineurin-dependent transcription factor NF(P)". <i>The Journal of Biological Chemistry</i> , Vol. 269, No. 30, pp. 19441-19446, 1994.		
	LEHMANN et al. "Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs". <i>The Journal of Biological Chemistry</i> Vol. 272, No. 6, pp. 3406-3410, February 7, 1997.		
	MARSHALL et al. "The jellyfish green fluorescent protein: A new tool for studying ion channel expression and function". <i>Neuron</i> , Vol. 14, pp. 211-215, February 1995.		
	MILLER et al. "Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression". <i>Adv. Exp. Medical Biology</i> , Vol. 461, pp. 107-116, 1999.		
	MURONO et al. "Aspirin inhibits tumor cell invasiveness induced by Epstein-barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression". <i>Cancer Research</i> , Vol. 60, pp. 2555-2561, May 1, 2000.		
	NAIR et al. "Cyclosporin A inhibits growth of autochthonous tumour cell lines by destabilizing interleukin-3 mRNA". <i>Letters to Nature</i> , Vol. 369, pp. 239-242, May 19, 1994.		
	NALCA et al. "The G <sub>1</sub> -phase growth-arresting action of interleukin-1 is independent of p53 and p21/WAF1 function". <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 46, pp. 30517-30523, November 13, 1998.		
	NEURATH et al. "Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice." <i>Nature Medicine</i> , Vol. 2, No. 9, pp. 998-1004, September 1996.		
	NORDEN. "Luciferase reported gene vectors for analysis of promoters and enhancers". <i>Biotechniques</i> , Vol. 6, No. 5, pp. 454-458, 1988.		
	OLIVER et al. "A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport." <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 98, pp. 5306-5311, April 24, 2001.		
	PIKAART et al. "Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators". <i>Genes &amp; Development</i> , Vol. 12, pp. 2852-2862, 1998.		
	RAO et al. "Transcription factors of the NFAT family: Regulation and function". <i>Annual Rev. Immunology</i> , Vol. 15, pp. 707-747, 1997.		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> <small>(Use several sheets if necessary)</small>		Docket Number: [REDACTED] 9555.126USWO	Application Number: 10/030,929
		Applicant: BLAIS et al.	
		Filing Date: 11 January 2002	Group Art Unit: unknown

*O I P E*  
JUN 13 2002  
USPTO  
PATENT & TRADEMARK OFFICE  
JC42

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	RIGGS et al. "Luciferase reporter gene cassettes for plant gene expression studies". <i>Nucleic Acids Research</i> , Vol. 15, No. 19, pp. 8115, 1987.
	ROTH et al. "Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer". <i>Nature Medicine</i> , Vol. 2, No. 9, pp. 985-991, September 1996.
	SEEGERS et al. "Fumonisins B <sub>1</sub> influenced the effects of arachidonic acid, prostaglandins E2 and A2 on the cell cycle progression, apoptosis induction, tyrosine- and CDC2-kinase activity in oesophageal cancer cells." <i>Prostaglandins, Leukotrienes, and Essential Fatty Acids</i> , Vol. 62, No. 2, pp. 75-84, 2000.
	SHIBASAKI et al. "Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4". <i>Nature</i> , Vol. 382, pp. 370-373, July 1996.
	SMITH et al. "Use of transcription factors as agents and targets for drug development". <i>Oncology</i> , Vol. 10, No. 10, pp. 1532-1542, 1996.
	STUNNENBERG. "Mechanisms of transactivation by retinoic acid receptors". <i>BioEssays</i> , Vol. 15, No. 5, pp. 309-315, May 1993.
	TENGKU-MUHAMMAD et al. "Cytokine-mediated differential regulation of macrophage activator protein-1-genes". <i>Cytokine</i> , Vol. 12, No. 6, pp. 720-726, June 2000.
	UDVARDY. "Dividing the empire: Boundary chromatin elements delimit the territory of enhancers". <i>The EMBO Journal</i> , Vol. 18, pp. 1-8, 1999.
	WATERMAN et al. "A single domain of the estrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene". <i>Molecular Endocrinology</i> , Vol. 2, pp. 14-21, 1988.
	YEI et al. "Green fluorescent protein as a vital marker and reporter of gene expression in <i>Drosophila</i> ". <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 1036-1040, July 1995.
	ZEITOUN et al. "Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same <i>cis</i> -acting element". <i>Molecular Endocrinology</i> , Vol. 13, pp. 239-253, 1999.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	